Navigation Links
A New Way to Get Chemo to Pancreatic Tumors
Date:5/21/2009

Technique that doubles life span in mice may hold hope for people,,

THURSDAY, May 21 (HealthDay News) -- Researchers are reporting that they've discovered a way to boost chemotherapy and slightly extend the lives of mice with pancreatic cancer, potentially paving the way for more effective treatments in people.

There's no guarantee that the strategy would work in humans. And, even if it did, the researchers don't expect that it would add many months to people's lives.

Still, scientists are "cautiously optimistic," said Dr. David Tuveson, lead author of a study released online May 21 in Science and a researcher at the Cambridge Research Institute in England.

Questions about such factors as cost, though, remain to be answered, Tuveson acknowledged.

Pancreatic tumors are among the most difficult types of cancer to treat. Roughly 5 percent of people diagnosed with the more common form of the disease are expected to survive five years from diagnosis, according to the American Cancer Society.

"It usually gets diagnosed when it is already very advanced because the symptoms don't usually begin until the cancer is advanced," said Dr. Allyson J. Ocean, assistant professor of medicine at the Jay Monahan Center for Gastrointestinal Health at New York-Presbyterian Hospital/Weill Cornell Medical College in New York City. Pancreatic cancer is resistant to chemotherapy and radiation, she added, and tumors are often aggressive and likely to spread.

Doctors think the disease is especially difficult to treat with chemotherapy because the tumors don't have many blood vessels to carry drugs to where they need to be to kill cancer cells.

In the study, researchers genetically engineered mice to develop a form of pancreatic cancer. The scientists then gave them a chemotherapy drug called gemcitabine (Gemzar) and another compound they hoped would boost blood flow in the tumors.

The survival time of the mice, on average, doubled from 11 to 25 days when they were treated with the chemotherapy drug and the compound, which is known only by a code. That may not seem like much, Tuveson said, but in people, "a doubling of overall survival from six to 12 months would be meaningful."

Dr. Aaron Sasson, chief of gastrointestinal surgical oncology at the University of Nebraska Medical Center, pointed out that some previous pancreatic treatments have worked well in mice but failed in humans. But the researchers behind the new study may have discovered a "trick" to a more effective treatment, he said.

Nonetheless, it would be quite some time before the treatment could reach doctors' offices, he said. Cost could be an issue, too: Some chemotherapy drugs, he said, cost thousands of dollars a month.

In the big picture, the treatment might extend life span by just a few months, he said. But the strategy could help make tumors more vulnerable to other types of chemotherapy drugs.

"It's possible that other chemotherapy drugs that failed before could become effective," he said.

More information

The American Cancer Society has more on pancreatic cancer.



SOURCES: David Tuveson, M.D., researcher, Cambridge Research Institute, Cambridge, England; Aaron Sasson, M.D., associate professor, surgery, and chief, gastrointestinal surgical oncology, University of Nebraska Medical Center, Omaha; Allyson J. Ocean, M.D., assistant professor, medicine, Jay Monahan Center for Gastrointestinal Health, New York-Presbyterian Hospital/Weill Cornell Medical College, New York City; May 21, 2009, Science


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
2. Ginger Eases Nausea From Chemo
3. Study shows chemotherapy improves survival among older breast cancer patients
4. Chemotherapy Superior to New Drug for Early Breast Cancer
5. Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa
6. 3-Drug Combo Reduces Nausea After Chemo
7. Delivering Chemo Directly Into Brain Tumors Shows Promise
8. Chemo Combo Shows Promise Against Ovarian Cancer
9. Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers
10. Radiation-Chemo Combo Boosts Lung Cancer Outcomes
11. 3-drug chemotherapy combination increases organ preservation in patients with larynx cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A New Way to Get Chemo to Pancreatic Tumors
(Date:2/24/2017)... ... 2017 , ... With millions of Americans and people worldwide ... all are aware of our options and are empowered with strength and information ... of its newest edition of "Vision and Hearing" in USA Today, that will ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ability ... total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass ... , With ProGlass Prism users are given the tools and effects to generate ...
(Date:2/24/2017)... ... 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) announces ... See” body image mannequin art competition. Selected from 15 submissions from around the nation, ... at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, ... thought leadership , media relations, social media, content marketing and SEO, is ... powered through Act-On, an intuitive marketing automation platform. , Rosica will now offer ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an official 2017 partnership with The Jensie Gran Fondo of Marin. For the ... UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified ... year ended 31 December 2016 compared with the previous corresponding period. ... viewed here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: ... 2015: $15.7m; up 11%) Profit before tax of ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
(Date:2/23/2017)... COTTAGE, New York , February 23, 2017 /PRNewswire/ ... health implications arising from increasing caseload for varicose veins ... recorded across the globe are prompting the adoption of ... latest study on global endovenous laser therapy ... attention towards aftereffects of lifestyle choices and consequences of ...
Breaking Medicine Technology: